Stacey Cohen, MD, University of Washington, Seatlle, WA, provides an overview of the use of circulating tumor DNA (ctDNA) for the detection of cancer recurrence when it has not been found via imaging or other blood-based biomarkers, such as CEA. Historically, data on ctDNA for recurrence detection has been primarily observational and restricted to trials with a limited population, thus providing the rationale for a retrospective analysis of a real-world cohort to evaluate whether ctDNA can reliably predict cancer recurrence. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.